76 results about "Regulatory sequence" patented technology

The present disclosure provides methods and systems for identifying transcriptional regulatory modules (e.g., in non-coding portions of the genome), predicting gene regulation and expression, e.g., effects of non-coding mutations or chromosome rearrangements on the regulation and expression of the target genes, and designing and using modified regulatory sequences.

The invention discloses a 5 'UTR library, a recombinant expression vector and a genetically engineered bacterium for improving the yield of folamin in pathogenic bacterium Badei and application of the 5' UTR library and the genetically engineered bacterium, and belongs to the technical field of microbial genetic engineering. The method comprises the following steps: designing an SD region based on a 16S rRNA (ribosomal Ribonucleic Acid) 3'end complementary sequence of a Buddei pathogenic bacterium XBD101 serving as an original strain, regulating and controlling the number of bases between the SD sequence and an initiation codon AUG and optimizing an UTR secondary structure to construct a library containing 14 UTR sequences, and replacing three sequences N4A, N7A and N18A with the strongest translation ability in the library to the UTR region of a folamin synthesis key gene fclC, so as to obtain the folamin peptide. And finally, the capacity upgrading of the folamin chassis strain is realized, and an important support is provided for the industrial production of agricultural antibiotics.

A method for generating a gene regulatory sequence with a desired endophenotype profile includes obtaining a plurality of gene regulatory sequences and inputting the plurality of gene regulatory sequences into a machine-learning model trained to obtain a plurality of effect predictions corresponding to a plurality of endophenotypes. The method further includes selecting one or more desired endophenotypes based on the plurality of endophenotypes and selecting a gene regulatory sequence in accordance with the one or more desired endophenotypes.

The invention discloses a method for efficiently preparing fixed-point biotinylation recombinant protein in escherichia coli, and belongs to the technical field of biology. According to the invention, a weakened expression regulatory sequence regulates and encodes a biotin ligase (BirA) gene expression cassette and a target protein gene expression cassette encoding a sequence carrying a biotin receptor peptide tag (AVI-Tag) to be jointly constructed on an escherichia coli expression vector, so that efficient fixed-point biotinylation of a target protein in an escherichia coli body is realized. The method has the advantages of high biotinylation efficiency, high specificity, simplicity and convenience in operation and the like, can be widely applied to the fields of separation and purification of proteins, protein interaction research and the like, and has important practical application value.

The invention provides a nucleic acid construct which comprises an immune response regulatory sequence and a coding sequence of a reporter gene driven by a promoter sequence, and the immune response regulatory sequence comprises a transcription factor binding regulatory element RE which is co-stimulated and regulated by transcription factors AP-1 and CD28. The invention also provides an in-vitro immune effector function reporter gene cell model containing the nucleic acid construct, and the cell model can realize effector function activity determination performance of sensitive and potent signals so as to evaluate ADCC and ADCP killing action mechanisms and titers mediated by antibody-dependent disease cells designed by an Fc structural domain of a therapeutic antibody product. In addition, the immunosuppression and regulation efficacy of a targeted CTLA-4 or Abatacept mediated treatment method on a CD28 co-activation pathway can be evaluated.

Methods and compositions for treating a corneal wound and / or increasing a population of limbal epithelial stem cells (LESCs) and / or early transit amplifying cells (eTAs) in the limbal epithelium of a subject in need thereof. The methods can include administering a therapeutic agent to the subject that: i) results in an increase in concentration of IFITM1 (Interferon Induced transmembrane Protein 1) in the limbal epithelium of the subject; and / or ii) results in a decrease in concentration of OVOL1 (Ovo Like Zinc Finger 1) in the limbal epithelium of the subject. Also provided are adeno-associated viruses (AAVs). The AAVs comprise a heterologous nucleic acid sequence encoding IFITM1 or a variant thereof, operably linked to a regulatory sequence.

The invention discloses a temperature-controlled cleavage plasmid based on nut site deletion of a pL promoter as well as a construction method and application of the temperature-controlled cleavage plasmid. According to the invention, on the premise of keeping the lambda cI857-pL / pR temperature control regulation mode unchanged, the stability of the system under medium-high temperature culture conditions is improved; meanwhile, compared with other systems for realizing thermal stability through promoter mutation, the system disclosed by the invention effectively relieves the problem that the cracking efficiency is obviously reduced after temperature rise induction by carrying out directional deletion transformation on a downstream regulation sequence of the promoter, so that the cracking process is more sufficient and reliable, and particularly, host bacteria can still be efficiently cracked under the induction condition of 42 DEG C; the bacteria dissolving efficiency can reach 99.99% or above, and the problem that the thermal stability and the cracking efficiency are difficult to consider in the bacterial ghost preparation process is solved.

Systems and methods for generating a plurality of unique edits in a T1 seed of a plant are provided. In one example, a method includes transforming at least one expression cassette into a plant cell or plant tissue. The at least one expression cassette may comprise a nucleic acid encoding a DNA modifying enzyme; optionally, a nucleic acid encoding at least one guide RNA (gRNA); and a floral mosaic (FMOS) regulatory sequence wherein the FMOS regulatory sequence (i) mediates expression of the DNA modifying enzyme in at least one of a floral primordium cell and a floral reproductive organ, and (ii) mediates a plurality of edits in at least one of the floral primordium and the floral reproductive organ. The method may also include regenerating the plant cell or plant tissue into a TO plant having a plurality of T1 seeds, wherein the T1 seeds contain a plurality of unique edits.

The purpose of the present invention is to provide a transformant having excellent 2,3-butanediol production capability. Provided is a transformant of a hydrogen-oxidizing bacterium that grows in the co-presence of oxygen, the transformant being used for the production of 2,3-butanediol. In the transformant, (a) a nucleic acid encoding an enzyme for synthesizing acetolactate from pyruvic acid, (b) a nucleic acid encoding an enzyme for converting acetolactate into acetoin, (c) a nucleic acid encoding an enzyme for converting acetoin into 2,3-butanediol, and (d) a regulatory sequence operably linked to the nucleic acids (a) to (c) are introduced, wherein the nucleic acid (b) is located upstream of the nucleic acid (a) and the nucleic acid (c).

The invention discloses an inflammation regulation sequence of dairy cow mastitis and application thereof, and belongs to the technical field of biology, the inflammation regulation sequence is a regulation sequence responding to a gram-negative bacterium inflammation signal, the regulation sequence is a promoter sequence of a CXCL2 gene and is shown as SEQ ID NO: 1, and the regulation sequence is a promoter sequence of a CXCL2 gene and is shown as SEQ ID NO: 2. A regulatory sequence responding to a gram-positive bacterium inflammation signal, which is a promoter partial sequence of the NLRP3 gene and is as shown in SEQ ID NO: 2; the regulatory sequence responding to a gram-positive bacterium inflammation signal is a promoter reverse complementary sequence of the TLR2 gene and is shown as SEQ ID NO: 3; the endogenous inflammation regulation sequence provided by the invention is composed of genome elements of the dairy cow, and no exogenous coding gene is introduced, so that potential risks caused by exogenous proteins are avoided.

The present invention provides genetic constructs and methods for enhanced production of milk proteins in transgenic plants. The invention comprises novel nucleic acid constructs wherein regulatory sequences derived from plant genes are inserted into bovine casein coding sequences, resulting in increased protein accumulation when expressed in plant cells. In particular embodiments, the insertion of these regulatory sequences into casein coding sequences leads to enhanced protein accumulation in transgenic soybean plants compared to constructs lacking the regulatory sequences.

Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.

Provided herein, among other things, is a cell-based therapeutic for the treatment of a non-malignant disease of the lung. In some embodiments, the therapeutic may comprise a cell comprising a molecular circuit comprising: (i) a binding-triggered transcriptional switch (BTTS) that binds to RAGE (Receptor for Advanced Glycation Endproducts), (ii) a nucleic acid sequence encoding an immunosuppressive protein, a growth factor and / or an anti-fibrotic agent; and (iii) a regulatory sequence operably linked to (ii) that is responsive to the binding-triggered transcriptional switch, wherein binding of the binding-triggered transcriptional switch to RAGE activates expression of the immunosuppressive protein, growth factor and / or the anti-fibrotic agent in the lung. Alternatively or in addition, the therapeutic may be a T cell (Treg) comprising an engineered immune receptor that recognizes RAGE. Also provided is a method for decreasing inflammation in the lung and / or inducing repair of lung tissue.

This invention describes a novel gene regulatory sequence containing the promoter and enhancer sequences of the human cardiac troponin T gene (TNNT2) that selectively induces expression in cardiomyocytes. This novel TNNT2 promoter / enhancer composition can be used to induce adeno-associated virus gene expression, construct cell-type-specific expression vectors, or perform cardiac-specific transgenesis. The use of this novel promoter / enhancer composition is demonstrated by the expression of mAKAP shRNA and a mAKAP-derived anchor-disrupting peptide useful for the treatment of heart failure.

Provided herein are vectors with engineered regulatory sequences for expression of non-coding RNAs (ncRNAs). Regulatory sequences of expression vectors include a Pol III promoter and a binding site for a Pol II - associated transcription factor. Also provided are compositions comprising provided vectors and methods of using the same, e.g., for expression of ncRNAs, e.g., for gene editing.

A recombinant AAV (rAAV) suitable for use in treating adult onset neurodegeneration caused by granulin (GRN) haploinsufficiency, such as progranulin (PGRN)-related frontotemporal dementia (FTD), is provided. The rAAV comprises (a) an adeno-associated virus 1 capsid, and (b) a vector genome packaged in the AAV capsid, said vector genome comprising AAV inverted terminal repeats, a coding sequence for human progranulin, and regulatory sequences which direct expression of the progranulin. Also provided are a method for treating a human patient with PGRN-FTD and other adult onset neurodegeneration caused by granulin (GRN) haploinsufficiencies, comprising delivering to the central nervous system (CNS) a recombinant adeno-associated virus (rAAV) having an adeno-associated virus 1 (AAV1) capsid, said rAAV further comprising a vector genome packaged in the AAV capsid, said vector genome comprising AAV inverted terminal repeats, a coding sequence for human progranulin, and regulatory sequences which direct expression of the progranulin.

The present invention relates to minimal polypeptide-encoding RNA molecules, in particular, RNA molecules that lack or comprise shortened regulatory sequences as compared to those found in eukaryotic mRNAs, which are thus more amenable to chemical synthesis. The invention also encompasses compositions comprising distinct populations of said RNA molecules, each encoding a unique polypeptide, and methods for manufacturing and using the RNA molecules or compositions.

A dual component system for treating a genetic disorder is provided. The system includes (a) a gene editing vector comprising an expression cassette comprising a nucleic acid sequence encoding a nuclease and regulatory sequences that direct expression of the nuclease in a target cell comprising a PCSK9 gene; and (b) a donor vector comprising a nucleic acid sequence encoding an exogenous product for expression from the PCSK9 locus, wherein the inserted nucleic acid sequence does not encode PCSK9, wherein the system further comprises sequences that direct the nuclease to specifically targets the native PCSK9 gene locus; and wherein the native PCSK9 in the target cell is optionally ablated or reduced post-dosing with the dual component system.

Herein disclosed are compositions comprising synthetic chromosomes and methods of their use to treat diseases and disorders (e.g., cancers, genetic and autoimmune diseases). Specifically described are methods of constructing synthetic chromosome compositions bearing one or multiple genes as well as regulatory sequences that control expression of the gene(s) such that, when these are expressed from the synthetic chromosome in an animal cell, at least one medicinal gene product is reliably, faithfully and indefinitely produced by the animal cells. As an example, the presently disclosed compositions and methods are used to bioengineer cells to enable them to express the entire dystrophin gene and additional regulatory nucleic acid sequences under tightly controlled conditions, allowing the present methods and compositions to be used as cellular medicines for treatment of diseases such as muscular dystrophies.

The present disclosure provides nucleic acid constructs engineered to express therapeutic expression products from regulatory sequences that drive expression in hematopoietic cell populations. For example, the present disclosure includes nucleic acid constructs in which a first regulatory sequence drives expression of a first therapeutic expression product and a second regulatory sequence drives expression of a second therapeutic expression product. Nucleic acid constructs can be delivered to cells or subjects by viral vectors, including adenoviral vectors, e.g., for the treatment of cancer.

To provide methods and compositions for modulating a target genome.SOLUTION: The present disclosure relates to compositions, systems, and methods for targeting, editing, modifying, or manipulating DNA sequences (e.g., inserting a heterologous DNA sequence of interest at a target site in a mammalian genome) at one or more locations within the DNA sequence in a cell, tissue, or subject, e.g., in vivo or in vitro. The DNA sequence of interest may include, for example, a coding sequence, a regulatory sequence, or a gene expression unit. More specifically, the present disclosure provides a retrotransposon-based system for inserting a sequence of interest into a genome.SELECTED DRAWING: None

To provide methods and compositions for modulating a target genome.SOLUTION: The present disclosure relates to compositions, systems, and methods for targeting, editing, modifying, or engineering a DNA sequence (e.g., inserting a heterologous DNA sequence of interest into a target site of a mammalian genome) at one or more locations within a DNA sequence in a cell, tissue, or subject, e.g., in vivo or in vitro. The DNA sequence of interest may comprise, for example, a coding sequence, a regulatory sequence, a gene expression unit.SELECTED DRAWING: None

The invention discloses a BR response tea tree COR413 gene promoter, which can be used for efficiently promoting the expression of a COR413 gene. The nucleotide sequence of the promoter is shown in figure 2, and an upstream regulatory sequence of a tea tree COR413 gene is cloned to obtain a complete sequence of a basic element of the promoter. The promoter can regulate and control the expression of an arabidopsis thaliana GUS gene. The verification of the interaction of the BR transcription factors CsBZR2-1 and CsCOR413 is carried out by utilizing an EMSA (Empirical Mode Serum Albumin) experiment, and a regulation and control site is determined. Meanwhile, the CsCOR413 gene in tea tree leaves is silenced through a VIGS technology, and it is found that the CsCOR413 gene positively regulates and controls the cold resistance of tea trees. The gene has very important significance for fundamental research and production practice of tea germplasm innovation by using the gene in the future.

This invention relates to the field of plant molecular marker technology, specifically to an EST-SSR molecular marker primer set developed based on the transcriptome sequence of *Prunus campanulata* and its applications. The EST-SSR molecular marker primer set contains 19 pairs of primers, with sequences shown in SEQ ID Nos. 1–38. The EST-SSR molecular marker primers developed based on *Prunus campanulata* transcriptome data exhibit greater accuracy, stability, and effectiveness compared to traditional molecular markers. Furthermore, the EST-SSR markers are mostly distributed in regions related to gene coding regions or regulatory sequences, providing a theoretical basis and important technical means for *Prunus campanulata* germplasm resource identification, genetic diversity analysis, molecular-assisted breeding, and fingerprinting, and have promising application prospects.

Primers are provided that are capable of (i) specifically hybridizing to a genomic DNA fragment comprising an adaptor, or an amplicon thereof, and (ii) selectively amplifying GC-rich sequences of a genome. The primers can be employed to interrogate the methylation status of multiple gene regulatory sequences in parallel, e.g., to identify aberrantly methylated or demethylated gene regulatory sequences on a global genomic scale. Methods that utilize, and compositions and kits that include, such primers are also described.

The invention relates to the technical field of plant molecular markers, in particular to an EST-SSR (expressed sequence tag-simple sequence repeat) molecular marker primer group developed on the basis of a cerasus sikanensis transcriptome sequence and application. The EST-SSR molecular marker primer group comprises 19 pairs of primers, and the sequences of the primers are as shown in SEQ ID No.1-38. According to the EST-SSR molecular marker primer developed on the basis of cerasus sikanensis transcriptome data, the EST-SSR molecular marker has accuracy, stability and effectiveness compared with a traditional molecular marker, and the EST-SSR molecular marker is mostly distributed in a gene coding region or a region related to a regulatory sequence; a theoretical basis and an important technical means are provided for germplasm resource identification, genetic diversity analysis, molecular-assisted breeding and fingerprint construction of cerasus sikanensis, and the method has a good application prospect.

The technology described herein is directed to systems and methods for synthetic regulatory sequence design or production. In several aspects described herein are methods of designing and optionally synthesizing shortened or otherwise modified polynucleotide sequences from polynucleotide sequences with transcriptional regulatory functionality. In other aspects described herein are isolated nucleic acid modules and viral vectors, comprising said shortened or otherwise modified polynucleotide as designed or synthesized herein.

To provide a method for producing a plant with increased γ-aminobutyric acid content without causing sterility or dwarfism, and to provide the plant.SOLUTION: It has been found that, in a plant, introducing a mutation into a regulatory sequence upstream of a GABA-T gene and suppressing an expression level of the gene enable an increase in γ-aminobutyric acid content without causing sterility or dwarfism.SELECTED DRAWING: None

The invention discloses a construction method and application of an hMRGPRX3 humanized mouse model and an atopic dermatitis model, and relates to the technical field of disease model construction. The whole gene sequence of the human MRGPRX3 or a vector containing the gene sequence of the hMRGPRX3 is transferred into mouse genome DNA (Deoxyribonucleic Acid) by utilizing a transgenic technology, and a functional human hMRGPRX3 receptor can be simulated and expressed in a mouse model more truly by transferring upstream and downstream regulatory sequences of the hMRGPRX3 gene. The pruritus signal transduction mediated by the receptor in human dorsal root ganglion sensory neurons can be accurately simulated, and signal deviation caused by species difference of a traditional mouse model is overcome.

The present disclosure discloses a new Retron editing system and its application in Corynebacterium glutamicum gene editing, specifically discloses a new Retron editing system and demonstrates its application in Corynebacterium glutamicum gene editing, belonging to the technical field of biotechnology and genetic engineering. The new gene editing system provided by the present disclosure is obtained by modifying the existing Retron editing system, which improves the efficiency and capacity of gene editing. The gene editing system of the present disclosure is applied to the construction of a DNA fragment genomic in situ saturation mutation library, which has high construction efficiency, high mutation site coverage and comprehensive mutation types. This method has broad application prospects in the fields of multi-gene editing regulation, DNA regulatory sequence in situ library construction, protein coding gene in situ library construction, enzyme high-throughput screening and the like.